Living Cell Technologies closes IPO
Friday, 27 August, 2004
Living Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
The company is expected to move from the Newcastle stock exchange (NSX) to the ASX on September 1, and has been suspended from trading on the NSX in preparation.
"LCT is a unique biotechnology company with an international infrastructure, significant scientific and commercial potential and a clear path to market. Transferring to the ASX is a significant and strategic step in our development and the keen interest in our capital raising not only validates our hard work to date but will underscore continued success in further developing our unique technology," said CEO David Collinson in a statement.
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
